Oncology/Cancer Drugs Market Top Key Players: AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd.

A fresh report titled “Oncology/Cancer Drugs Market” has been presented by KD market insights. It evaluates the key market trends, advantages, and factors that are pushing the overall growth of the market. The report also analyzes the different segments along with major geographies that have more demand for Oncology/Cancer Drugs Market. The competition analysis is also a major part of the report.

The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Request for Sample @ https://www.kdmarketinsights.com/sample/3396

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits for Oncology Drugs Market:

– The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
– It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
– A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
– The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Oncology Drugs Key Market Segments:

By Drug Class Type
– Chemotherapy
– Targeted Therapy
– Immunotherapy (Biologic Therapy)
– Hormonal Therapy

By Indication
– Lung Cancer
– Stomach Cancer
– Colorectal Cancer
– Breast Cancer
– Prostate Cancer
– Liver Cancer
– Esophagus Cancer
– Cervical Cancer
– Kidney Cancer
– Bladder Cancer
– Other Cancers

By Region
North America
– U.S.
– Canada
– Mexico
Europe
– Germany
– France
– UK
– Italy
– Spain
– Rest of Europe
Asia-Pacific
– India
– China
– Japan
– Australia
– South Korea
– Rest of Asia-Pacific
LAMEA
– Brazil
– South Africa
– Saudi Arabia
– Rest of LAMEA

List of Key Players Profiled in the Report
– AbbVie Inc.
– Astellas Pharma Inc.
– AstraZeneca PLC
– Bristol-Myers Squibb Company
– Celgene Corporation
– F. Hoffmann-La Roche Ltd.
– Johnson & Johnson (Janssen Global Services, LLC,)
– Merck & Co., Inc.
– Novartis AG
– Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
– Sanofi
– Amgen Inc.
– Bayer AG
– Exelixis, Inc.

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/oncology-cancer-drugs-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017

3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Patent analysis (2015-2018)

3.6.1. Patent analysis, world
3.6.2. Patent analysis, by year

3.7. Market dynamics

3.7.1. Drivers

3.7.1.1. Rise in incidence of cancer across the globe
3.7.1.2. Surge in global geriatric population
3.7.1.3. Increase in government expenditures on healthcare

3.7.2. Restraints

3.7.2.1. Adverse effects associated with the use of cancer drugs

3.7.3. Opportunities

3.7.3.1. Untapped emerging economies
3.7.3.2. Increase in number of pipeline drugs

3.7.4. Impact Analyses

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Chemotherapy

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Targeted Therapy

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Immunotherapy (Biologic Therapy)

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Hormonal Therapy

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Lung Cancer

5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country

5.3. Stomach Cancer

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Colorectal Cancer

5.4.1. Market size and forecast, by region
5.4.2. Market share analysis, by country

5.5. Breast Cancer

5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country

5.6. Prostate Cancer

5.6.1. Market size and forecast, by region
5.6.2. Market share analysis, by country

5.7. Liver Cancer

5.7.1. Market size and forecast, by region
5.7.2. Market share analysis, by country

5.8. Esophagus Cancer

5.8.1. Market size and forecast, by region
5.8.2. Market share analysis, by country

5.9. Cervical Cancer

5.9.1. Market size and forecast, by region
5.9.2. Market share analysis, by country

5.10. Kidney Cancer

5.10.1. Market size and forecast, by region
5.10.2. Market share analysis, by country

5.11. Bladder Cancer

5.11.1. Market size and forecast, by region
5.11.2. Market share analysis, by country

5.12. Other Cancers

5.12.1. Market size and forecast, by region
5.12.2. Market share analysis, by country

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type
6.2.2.1.2. U.S. oncology/cancer drugs market, by indication

6.2.2.2. Canada

6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2. Canada oncology/cancer drugs market, by indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2. Mexico oncology/cancer drugs market, by indication

6.2.3. Market size and forecast, by drug class type
6.2.4. Market size and forecast, by indication

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2. Germany oncology/cancer drugs market, by indication

6.3.2.2. France

6.3.2.2.1. France oncology/cancer drugs market, by drug class type
6.3.2.2.2. France oncology/cancer drugs market, by indication

6.3.2.3. UK

6.3.2.3.1. UK oncology/cancer drugs market, by drug class type
6.3.2.3.2. UK oncology/cancer drugs market, by indication

6.3.2.4. Italy

6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2. Italy oncology/cancer drugs market, by indication

6.3.2.5. Spain

6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2. Spain oncology/cancer drugs market, by indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication

6.3.3. Market size and forecast, by drug class type
6.3.4. Market size and forecast, by indication

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2. Japan oncology/cancer drugs market, by indication

6.4.2.2. China

6.4.2.2.1. China oncology/cancer drugs market, by drug class type
6.4.2.2.2. China oncology/cancer drugs market, by indication

6.4.2.3. Australia

6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2. Australia oncology/cancer drugs market, by indication

6.4.2.4. India

6.4.2.4.1. India oncology/cancer drugs market, by drug class type
6.4.2.4.2. India oncology/cancer drugs market, by indication

6.4.2.5. South Korea

6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2. South Korea oncology/cancer drugs market, by indication

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication

6.4.3. Market size and forecast, by drug class type
6.4.4. Market size and forecast, by indication

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2. Brazil oncology/cancer drugs market, by indication

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication

6.5.2.3. South Africa

6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2. South Africa oncology/cancer drugs market, by indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication

6.5.3. Market size and forecast, by drug class type
6.5.4. Market size and forecast, by indication

Continue…

Check for Discount @ https://www.kdmarketinsights.com/discount/3396

Contact Us

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: sales@kdmarketinsights.com

Website: www.kdmarketinsights.com

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

This release was published on openPR.